Skip to main content
    S

    Scynexis Inc (SCYX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.90
    -0.31 (-9.66%)

    Market Cap: $31.95M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Scynexis Inc (SCYX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Scynexis (SCYX) trades at 1.8x sales and 0.6x book value. Its P/B of 0.6x is below its 5-year median of 1.2x. Its forward P/E is 1.9x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E1.9x
    Price to sales1.8x
    Price to book0.6x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 72.7% below 2.2x.

    MultipleCurrent5-year median10-year median
    P/B0.6x1.2x2.2x
    Medians of month-end values through Oct 2026: 57 months (5-year) and 115 months (10-year).

    Valuation History

    Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 0.8x in 2023 to 384.4x in 2019.

    Year endPriceP/EP/SP/B
    2025$5.069.4x1.4x0.6x
    2024$9.68N/A6.8x1.0x
    2023$17.841.0x0.8x1.5x
    2022$12.48N/A11.9x15.8x
    2021$48.80N/AN/A4.3x
    2020$61.20N/AN/A12.1x
    2019$72.80N/A384.4x6.9x
    2018$38.54N/A80.9x0.8x
    2017$185.60N/A249.4x3.6x
    2016$255.20N/A223.3x2.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SCYX

    What is SCYX's forward P/E ratio?

    Scynexis has a forward P/E ratio of 1.9x.

    Is SCYX stock overvalued?

    GNG's valuation label for SCYX is Undervalued.

    What is SCYX's price to sales ratio?

    Scynexis has a price to sales ratio of 1.8x.